Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells
PLoS ONE, ISSN: 1932-6203, Vol: 6, Issue: 7, Page: e21924
2011
- 49Citations
- 65Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations49
- Citation Indexes49
- 49
- CrossRef43
- Captures65
- Readers65
- 65
Article Description
Challenges today concern chronic myeloid leukemia (CML) patients resistant to imatinib. There is growing evidence that imatinib-resistant leukemic cells present abnormal glucose metabolism but the impact on mitochondria has been neglected. Our work aimed to better understand and exploit the metabolic alterations of imatinib-resistant leukemic cells. Imatinib-resistant cells presented high glycolysis as compared to sensitive cells. Consistently, expression of key glycolytic enzymes, at least partly mediated by HIF-1α, was modified in imatinib-resistant cells suggesting that imatinib-resistant cells uncouple glycolytic flux from pyruvate oxidation. Interestingly, mitochondria of imatinib-resistant cells exhibited accumulation of TCA cycle intermediates, increased NADH and low oxygen consumption. These mitochondrial alterations due to the partial failure of ETC were further confirmed in leukemic cells isolated from some imatinib-resistant CML patients. As a consequence, mitochondria generated more ROS than those of imatinib-sensitive cells. This, in turn, resulted in increased death of imatinib-resistant leukemic cells following in vitro or in vivo treatment with the pro-oxidants, PEITC and Trisenox, in a syngeneic mouse tumor model. Conversely, inhibition of glycolysis caused derepression of respiration leading to lower cellular ROS. In conclusion, these findings indicate that imatinib-resistant leukemic cells have an unexpected mitochondrial dysfunction that could be exploited for selective therapeutic intervention. © 2011 Kluza et al.
Bibliographic Details
10.1371/journal.pone.0021924; 10.1371/journal.pone.0021924.g007; 10.1371/journal.pone.0021924.g006; 10.1371/journal.pone.0021924.g003; 10.1371/journal.pone.0021924.g002; 10.1371/journal.pone.0021924.g005; 10.1371/journal.pone.0021924.g001; 10.1371/journal.pone.0021924.g004
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=79960630736&origin=inward; http://dx.doi.org/10.1371/journal.pone.0021924; http://www.ncbi.nlm.nih.gov/pubmed/21789194; https://dx.plos.org/10.1371/journal.pone.0021924.g007; http://dx.doi.org/10.1371/journal.pone.0021924.g007; https://dx.plos.org/10.1371/journal.pone.0021924.g006; http://dx.doi.org/10.1371/journal.pone.0021924.g006; https://dx.plos.org/10.1371/journal.pone.0021924.g003; http://dx.doi.org/10.1371/journal.pone.0021924.g003; https://dx.plos.org/10.1371/journal.pone.0021924.g002; http://dx.doi.org/10.1371/journal.pone.0021924.g002; https://dx.plos.org/10.1371/journal.pone.0021924.g005; http://dx.doi.org/10.1371/journal.pone.0021924.g005; https://dx.plos.org/10.1371/journal.pone.0021924; https://dx.plos.org/10.1371/journal.pone.0021924.g001; http://dx.doi.org/10.1371/journal.pone.0021924.g001; https://dx.plos.org/10.1371/journal.pone.0021924.g004; http://dx.doi.org/10.1371/journal.pone.0021924.g004; https://dx.doi.org/10.1371/journal.pone.0021924; https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0021924; https://dx.doi.org/10.1371/journal.pone.0021924.g002; https://journals.plos.org/plosone/article/figure?id=10.1371/journal.pone.0021924.g002; https://dx.doi.org/10.1371/journal.pone.0021924.g001; https://journals.plos.org/plosone/article/figure?id=10.1371/journal.pone.0021924.g001; https://dx.doi.org/10.1371/journal.pone.0021924.g004; https://journals.plos.org/plosone/article/figure?id=10.1371/journal.pone.0021924.g004; https://dx.doi.org/10.1371/journal.pone.0021924.g007; https://journals.plos.org/plosone/article/figure?id=10.1371/journal.pone.0021924.g007; https://dx.doi.org/10.1371/journal.pone.0021924.g006; https://journals.plos.org/plosone/article/figure?id=10.1371/journal.pone.0021924.g006; https://dx.doi.org/10.1371/journal.pone.0021924.g003; https://journals.plos.org/plosone/article/figure?id=10.1371/journal.pone.0021924.g003; https://dx.doi.org/10.1371/journal.pone.0021924.g005; https://journals.plos.org/plosone/article/figure?id=10.1371/journal.pone.0021924.g005; http://dx.plos.org/10.1371/journal.pone.0021924.g003; http://dx.plos.org/10.1371/journal.pone.0021924.g001; http://dx.plos.org/10.1371/journal.pone.0021924.g007; http://dx.plos.org/10.1371/journal.pone.0021924.g002; https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0021924&type=printable; http://dx.plos.org/10.1371/journal.pone.0021924.g005; http://www.plosone.org/article/metrics/info:doi/10.1371/journal.pone.0021924; http://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0021924&type=printable; http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0021924; http://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0021924; http://dx.plos.org/10.1371/journal.pone.0021924; http://dx.plos.org/10.1371/journal.pone.0021924.g004; http://dx.plos.org/10.1371/journal.pone.0021924.g006
Public Library of Science (PLoS)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know